 |
|
COMMENTS AND OPINIONS
Status Epilepticus in Patients With CNS Metastases
Svetlana Blitshteyn, MD;
Kurt A. Jaeckle, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
We read with interest the study by Cavaliere et al.1 We are particularly intrigued by their report of a 30-day mortality rate of 50% in patients with systemic cancer and brain metastases presenting in convulsive status epilepticus (CSE). We have recently reported a series of 4 patients with systemic cancer presenting in de novo nonconvulsive status epilepticus (NCSE) who were diagnosed with metastatic CNS disease via brain imaging at the time of presentation.2 All patients demonstrated improvement in mental status after treatment with anticonvulsants; however, 2 patients died at 5 and 20 days, respectively, after the onset of NCSE. Although the number of patients in our series was small, the 30-day mortality of 50% in patients with NCSE is the same as in the series by Cavaliere et al of 10 patients with systemic cancer and CSE.
Nonconvulsive status epilepticus is a more . . . [Full Text of this Article] AUTHOR INFORMATION
RELATED LETTER
Status Epilepticus in Patients With CNS Metastases—Reply
David Schiff and Robert Cavaliere
Arch Neurol. 2007;64(6):916-917.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Clinical Implications of Status Epilepticus in Patients With Neoplasms
Robert Cavaliere, Elana Farace, and David Schiff
Arch Neurol. 2006;63(12):1746-1749.
ABSTRACT
| FULL TEXT
|
